Apotex/Novopharm Lovastatin Trial To Reopen
A Manitoba, Canada, Court of Appeal judge has ruled that a C$5 million ($3.7 million) judgement awarded to Canadian generic drug company Apotex in September in relation to fellow Canadian company Novopharm and the anticholesterol agent lovastatin (Marketletter September 18, 1995) be set aside and the trial reopened.
Novopharm was ordered to pay damages after the firm was found guilty of stealing secrets from Apotex in relation to the drug. Apotex tried to preserve the decision made in September by arguing that company officials did not realize the Y-5 formula used in production of lovastatin was being disclosed in the patent application filed in August 1993, according to local press reports. A date for the retrial has not been set.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze